2.64
4.35%
-0.12
LAVA Therapeutics NV Borsa (LVTX) Ultime notizie
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect? - Yahoo Singapore News
Yahoo Singapore News
How Much Of LAVA Therapeutics N.V. (NASDAQ:LVTX) Do Institutions Own? - Yahoo New Zealand News
Yahoo New Zealand News
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference - GlobeNewswire
GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference - Yahoo Finance
Yahoo Finance
LAVA Therapeutics Announces Progress and Stability - TipRanks.com - TipRanks
TipRanks
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results - GlobeNewswire
GlobeNewswire
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
GlobeNewswire Inc.
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA ... - GlobeNewswire
GlobeNewswire
LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Simply Wall St
Healthcare Stocks on the Move Thursday: LVTX, SCTL, ENVB, RNLX, KA, IRWD, AMPE, GRFS - InvestorsObserver
InvestorsObserver
LVTX Stock Quote Price and Forecast - CNN
CNN
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
Benzinga
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
GlobeNewswire Inc.
LAVA stock rises on clinical trial collaboration with Merck (NASDAQ:LVTX) - Seeking Alpha
Seeking Alpha
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results - Yahoo Finance
Yahoo Finance
Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall - Nasdaq
Nasdaq
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway - GlobeNewswire
GlobeNewswire
LAVA Therapeutics Announces Initial Data from Ongoing Phase 1/2a Trial of LAVA-1207 - Investing.com South Africa
Investing.com South Africa
Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava - BioCentury
BioCentury
LAVA Therapeutics: Assessing A Promising Innovator (NASDAQ:LVTX) - Seeking Alpha
Seeking Alpha
Seagen and Lava enter license agreement for γδ bispecific T-cell engager LAVA-1223 - BioWorld Online
BioWorld Online
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a ... - Business Wire
Business Wire
LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022 - GlobeNewswire
GlobeNewswire
LAVA Therapeutics Expands Management Team with Three Key Appointments - GlobeNewswire
GlobeNewswire
Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager ... - Business Wire
Business Wire
Capitalizzazione:
|
Volume (24 ore):